Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: A novel therapeutic approach for breast cancer and breast cancer stem cells

Drug Delivery and Translational Research

Volumn 3, Issue 6, 2013, Pages 562-574

  Gülçür, Ece ^a   Thaqi, Mentor ^b   Khaja, Fatima ^a   Kuzmis, Antonina ^a   Önyüksel, Hayat ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University of Illinois at Chicago   (United States)

Author keywords

Breast cancer stem cells; Curcumin; Nanoparticles; Sterically stabilized phospholipid micelles; Targeted drug delivery; Vasoactive intestinal peptide

Indexed keywords

CURCUMIN; LIPID; PHOSPHOLIPID; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG STABILITY; FEASIBILITY STUDY; FREEZE DRYING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NANOENCAPSULATION; NANOMEDICINE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN TARGETING;

EID: 84887189409     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-013-0167-6     Document Type: Article

References (56)

1. Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztl Int. 2010;107: 85-91.
2. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer. 2008;44: 2781-90.
3. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120: 41-50.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414: 105.
5. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006;66: 9339-44.
6. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98: 1777-85.
7. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100: 672-9.
8. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138: 645-59.
9. Chen J, Li Y, Yu T-S, McKay RM, Kernie SG, Parada LF, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488: 522-6.
10. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumor growth by clonal analysis. Nature. 2012;488: 527-30.
11. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science. 2012;337: 730-5.
12. Aggarwal BB, Surh Y, Shishodia S. Advances in experimental medicine and biology: the molecular targets and therapeutic uses of curcumin in health and disease. eBook. New York, NY: Springer; 2007.
13. López-Lázaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008;52: 103-27.
14. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62: 919-30.
15. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15: 195-218.
16. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008;267: 133-64.
17. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14: 4491-9.
18. Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vené R, et al. The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem. 2007;19: 1-4.
19. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005;11: 7490-8.
20. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144: 646-74.
21. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol. 2009;2: 321-8.
22. Fong D, Yeh A, Naftalovich R, Choi TH, Chan MM. Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett. 2010;293: 65-72.
23. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat. 2010;122: 777-85.
24. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity, and stem-like fraction in malignant brain tumors. Cancer Biol Ther. 2011;11: 464-73.
25. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4: 807-18.
26. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila). 2011;4: 1158-71.
27. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res. 2001;21: 2895-900.
28. Önyüksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm. 2009;365: 157-61.
29. Krishnadas A, Rubinstein I, Onyuksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm Res. 2003;20: 297-302.
30. Koo OM, Rubinstein I, Onyuksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res. 2011;28: 776-87.
31. Lim SB, Rubinstein I, Sadikot RT, Artwohl JE, Önyüksel H. A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles. Pharm Res. 2011;28: 662-72.
32. Working PK, Dayan AD. Pharmacological-toxicological expert report. CAELYX. (stealth liposomal doxorubicin HCl). Hum Exp Toxicol. 1996;15: 751-85.
33. Vukovic L, Khatib FA, Drake SP, Madriaga A, Brandenburg KS, Kral P, et al. Structure and dynamics of highly PEG-ylated sterically stabilized micelles in aqueous media. J Am Chem Soc. 2011;133: 13481-8.
34. Ashok B, Arleth L, Hjelm RP, Rubinstein I, Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci. 2004;93: 2476-87.
35. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2: 751-60.
36. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46: 6387-92.
37. Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation, and pharmacology. Peptides. 2007;28: 1631-9.
38. Onyukse H, Banerjee A. Phospholipid-based nanomicelles in cancer nanomedicine. In: Hunter RJ, Preedy VR. Nanomedicine in health and disease. Boca Raton, FL; Jersey, British Isles; Enfield, N. H.: CRC Press; Science Publishers; 2011. pp. 314-35.
39. Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000;60: 3105-12.
40. Dagar S, Sekosan M, Rubinstein I, Onyüksel H. Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Breast Cancer Res Treat. 2001;65: 49-54.
41. Gespach C, Bawab W, de Cremoux P, Calvo F. Pharmacology, molecular identification, and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res. 1988;48: 5079-83.
42. Onyuksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 2009;274: 327-30.
43. Schatzlein AG. Cancer stem cells: opportunities for novel diagnostics and drug discovery. Delivering cancer stem cell therapies-a role for nanomedicines? Eur J Cancer. 2006;42: 1309-15.
44. Callihan P, Mumaw J, Machacek DW, Stice SL, Hooks SB. Regulation of stem cell pluripotency and differentiation by G protein coupled receptors. Pharmacol Ther. 2011;129: 290-306.
45. Dagar S, Sekosan M, Lee BS, Rubinstein I, Önyüksel H. VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery. J Control Release. 2001;74: 129-34.
46. Lim SB, Rubinstein I, Onyuksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible, and biodegradable sterically stabilized phospholipid nanomicelles. Int J Pharm. 2008;356: 345-50.
47. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1: 1112-6.
48. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes. Dev. 2003;1253-1270.
49. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65: 5506-11.
50. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100(7): 3983-8.
51. Koo OM, Rubinstein I, Onyuksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine. 2005;1: 77-84.
52. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials. 2010;31: 6597-611.
53. Valdehita A, Bajo AM, Fernandez-Martinez AB, Arenas MI, Vacas E, Valenzuela P, et al. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides. 2010;31: 2035-45.
54. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29: 4741-51.
55. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7: 653-64.
56. Tonnesen HH, Masson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. cyclodextrin complexation: solubility, chemical, and photochemical stability. Int J Pharm. 2002;244: 127-35.